Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2013; 19(32): 5302-5308
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5302
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5302
Characteristic | Elevated group (n = 163) | Non-elevated group (n = 325 ) | P value |
Sex | 0.963 | ||
Male | 111 (68.1) | 222 (68.3) | |
Female | 52 (31.9) | 103 (31.7) | |
Mean age, yr (range) | 60.70 ± 12.00 (29-84) | 59.71 ± 12.40 (27-85) | 0.295 |
Number of lesions | 0.436 | ||
Single | 145 (89.0) | 281 (86.5) | |
Multiple | 18 (11.0) | 44 (13.5) | |
Size (cm) | |||
Horizontal | 6.38 ± 3.51 | 5.78 ± 3.16 | 0.060 |
Vertical | 5.15 ± 2.79 | 4.66 ± 2.60 | 0.053 |
Endoscopic findings | 0.135 | ||
EGC | |||
Elevated | 10 (6.1) | 23 (7.1) | |
Flat | 3 (1.8) | 15 (1.6) | |
Depressed | 10 (6.1) | 18 (5.5) | |
AGC | |||
Borrmann I | 9 (5.5) | 8 (2.5) | |
Borrmann II | 25 (15.3) | 38 (11.7) | |
Borrmann III | 89 (54.6) | 203 (62.5) | |
Borrmann IV | 17 (10.4) | 20 (6.2) | |
Histology | 0.033 | ||
Well differentiated | 19 (11.7) | 23 (7.1) | |
Moderately differentiated | 57 (35.0) | 86 (26.5) | |
Poorly differentiated | 54 (33.1) | 145 (44.6) | |
Signet ring cell cancer | 33 (20.3) | 71 (21.9) | |
Location | 0.404 | ||
Lower | 108 (66.3) | 210 (61.6) | |
Middle | 16 (9.8) | 49 (15.1) | |
Upper | 31 (19.0) | 52 (16.0) | |
Diffuse | 8 (1.9) | 14 (4.3) | |
T stage | 0.843 | ||
T0-2 | 55 (36.7) | 117 (37.6) | |
T3, 4 | 95 (63.3) | 194 (62.4) | |
N stage | 0.908 | ||
N0, 1 | 79 (52.7) | 162 (52.1) | |
N2, 3 | 71 (47.3) | 149 (47.9) | |
Mean metastatic | 0.893 | ||
Lymph nodes (N) | 9.88 ± 13.03 | 10.09 ± 11.94 | |
TNM stage | > 0.999 | ||
0 | 1 (0.6) | 2 (0.6) | |
I | 26 (16.0) | 52 (16.0) | |
II | 21 (12.9) | 42 (12.9) | |
III | 57 (35.0) | 114 (35.1) | |
IV | 58 (35.6) | 115 (35.4) | |
Operation | 0.114 | ||
For radical | 139 (85.3) | 293 (90.2) | |
For palliative | 24 (14.7) | 32 (0.8) | |
Lymphovascular invasion | 0.225 | ||
Positive | 98 (76.0) | 190 (70.1) | |
Negative | 31 (24.0) | 81 (29.9) | |
Peritoneal metastasis | 0.899 | ||
Positive | 10 (6.1) | 19 (5.8) | |
Negative | 153 (93.9) | 306 (94.2) | |
Hepatic metastasis | 0.853 | ||
Positive | 5 (3.1) | 11 (3.4) | |
Negative | 158 (96.9) | 314 (96.6) | |
Neoadjuvant chemotherapy | 0.217 | ||
Positive | 6 (3.7) | 6 (1.8) | |
Negative | 157 (96.3) | 319 (98.2) | |
Mean serum CA 19-9 (range) | 575.74 ± 518.09 (37.4-12800) | 8.45 ± 8.42 (0-36.8) | < 0.001 |
Mean serum CEA (range) | 6.00 ± 21.86 (0.01-260.27) | 5.49 ± 17.30 (0.01-189.21) | 0.777 |
Mean serum CA 72-4 (range) | 9.31 ± 20.52 (0.33-164) | 14.42 ± 68.61 (0.2-600) | 0.376 |
- Citation: Choi AR, Park JC, Kim JH, Shin SK, Lee SK, Lee YC, Chung JB. High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol 2013; 19(32): 5302-5308
- URL: https://www.wjgnet.com/1007-9327/full/v19/i32/5302.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i32.5302